The Cooper Companies, Inc.

COO Healthcare Medical Instruments & Supplies

The Cooper Companies, Inc.’s revenue for fiscal 2025 (year ended October 2025) was $4.1 billion, up 5.06% from fiscal 2024.

Revenue
+0.56%
EPS
+357.1%
Free cash flow
+66.0%
Total debt
+2.66%

Quarter to July 2026, against a year earlier

62.80 0.71 −1.12%
Market cap
$12.1B
P/E
21.7×
Fwd P/E
17.5×
Dividend yield
—
F-score
5/9
Altman Z
3.48
Beneish M
−2.50
Dividend safety
n/a

The Cooper Companies, Inc. 10-Q filed Aug 28, 2025

Fiscal Q3 2025 · Period ended Jul 31, 2025 · Filed · accepted 4:18 PM ET · Document on sec.gov · Filing index

What changed

Part I, Item 2, Management’s Discussion and Analysis, against the 10-Q filed May 30, 2025: 6 added · 3 removed · 18 modified; 11 with only figures updated

  1. Modified · CooperVision Net Sales by Category

    In the three and sixnine months ended April 30July 31, 2025, the growth experienced across all categories was partially offsetpositively impacted by unfavorablefavorable foreign exchange rate fluctuations of approximately $7.726.8 million and $22.44.4 million, respectively.